{"brief_title": "Phase I Study of Isotretinoin in Patients With Recessive Dystrophic Epidermolysis Bullosa", "brief_summary": "OBJECTIVES: I. Determine the safety of isotretinoin in patients with recessive dystrophic epidermolysis bullosa.", "detailed_description": "PROTOCOL OUTLINE: Patients receive oral isotretinoin daily for 8 months in the absence of disease progression or unacceptable toxicity. Completion date provided represents the completion date of the grant per OOPD records", "condition": ["Epidermolysis Bullosa"], "intervention_type": ["Drug"], "intervention_name": ["isotretinoin"], "criteria": "PROTOCOL ENTRY CRITERIA: --Disease Characteristics-- - Diagnosis of recessive dystrophic epidermolysis bullosa (RDEB) RDEB Hallopeau-Siemens OR RDEB non-Hallopeau-Siemens - Concurrent enrollment in the National Epidermolysis Bullosa Registry - No regional or distant metastasis in patients with previous or concurrent squamous cell carcinoma --Patient Characteristics-- - Hepatic: No clinically significant hypertriglyceridemia No clinically significant hepatic dysfunction - Renal: No clinically significant renal dysfunction - Other: Not pregnant or nursing Negative pregnancy test Fertile patients must use effective contraception", "gender": "All", "minimum_age": "15 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "keyword": "rare disease", "mesh_term": ["Epidermolysis Bullosa", "Epidermolysis Bullosa Dystrophica", "Isotretinoin"], "id": "NCT00014729"}